Technical Analysis for RLAY - Relay Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Historical RLAY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 50 DMA Support | Bullish | -6.85% | |
| Crossed Above 200 DMA | Bullish | -6.85% | |
| Crossed Above 20 DMA | Bullish | -6.85% | |
| MACD Bullish Signal Line Cross | Bullish | -6.85% | |
| Pocket Pivot | Bullish Swing Setup | -6.85% | |
| Volume Surge | Other | -6.85% | |
| Wide Bands | Range Expansion | -6.85% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | 3 days ago |
| 60 Minute Opening Range Breakdown | 3 days ago |
| Down 5% | 3 days ago |
| Down 1 ATR | 3 days ago |
| Down 3% | 3 days ago |
Get a Trading Sidekick!
- Earnings date: 11/10/2021
Relay Therapeutics, Inc. Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Receptors Tyrosine Kinase Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Metastatic Solid Tumors Fibroblast Growth Factor Receptor 2 Ptpn11
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 64.0 |
| 52 Week Low | 25.72 |
| Average Volume | 929,775 |
| 200-Day Moving Average | 36.26 |
| 50-Day Moving Average | 32.80 |
| 20-Day Moving Average | 32.82 |
| 10-Day Moving Average | 30.35 |
| Average True Range | 2.94 |
| ADX | 27.87 |
| +DI | 30.53 |
| -DI | 19.63 |
| Chandelier Exit (Long, 3 ATRs) | 29.32 |
| Chandelier Exit (Short, 3 ATRs) | 34.55 |
| Upper Bollinger Bands | 40.34 |
| Lower Bollinger Band | 25.30 |
| Percent B (%b) | 0.59 |
| BandWidth | 45.81 |
| MACD Line | -0.46 |
| MACD Signal Line | -0.81 |
| MACD Histogram | 0.3449 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 39.33 | ||||
| Resistance 3 (R3) | 39.62 | 38.18 | 38.46 | ||
| Resistance 2 (R2) | 38.18 | 36.85 | 38.03 | 38.17 | |
| Resistance 1 (R1) | 36.14 | 36.03 | 35.42 | 35.85 | 37.88 |
| Pivot Point | 34.70 | 34.70 | 34.34 | 34.55 | 34.70 |
| Support 1 (S1) | 32.66 | 33.37 | 31.94 | 32.37 | 30.34 |
| Support 2 (S2) | 31.22 | 32.55 | 31.07 | 30.05 | |
| Support 3 (S3) | 29.18 | 31.22 | 29.76 | ||
| Support 4 (S4) | 28.89 |
